InvestorsHub Logo
Followers 2092
Posts 89903
Boards Moderated 0
Alias Born 12/17/2011

Re: None

Monday, 07/06/2020 8:04:44 AM

Monday, July 06, 2020 8:04:44 AM

Post# of 1121
ACST...53...Christine Brown- July 6, 2020, 6:54 AM EDTSHARE ON:
In a report released today, Mayank Mamtani from B.Riley FBR maintained a Buy rating on Acasti Pharma (ACST), with a price target of $2.00. The company’s shares closed last Thursday at $0.53, close to its 52-week low of $0.25.
According to TipRanks.com, Mamtani is a 5-star analyst with an average return of 22.1% and a 52.1% success rate. Mamtani covers the Healthcare sector, focusing on stocks such as Arrowhead Pharmaceuticals, Spectrum Pharmaceuticals, and Madrigal Pharmaceuticals.
Currently, the analyst consensus on Acasti Pharma is a Moderate Buy with an average price target of $3.34, a 554.9% upside from current levels. In a report issued on June 30, Oppenheimer also maintained a Buy rating on the stock with a $7.00 price target...:party:

Ones entry is only as good as the exit strategy...

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ACST News